Allergology International (Jul 2017)

Utility of serum periostin in combination with exhaled nitric oxide in the management of asthma

  • Tadao Nagasaki,
  • Hisako Matsumoto,
  • Kenji Izuhara,
  • Yoshihiro Kanemitsu,
  • Yuji Tohda,
  • Takahiko Horiguchi,
  • Hideo Kita,
  • Keisuke Tomii,
  • Masaki Fujimura,
  • Akihito Yokoyama,
  • Yasutaka Nakano,
  • Soichiro Hozawa,
  • Isao Ito,
  • Tsuyoshi Oguma,
  • Yumi Izuhara,
  • Tomoko Tajiri,
  • Toshiyuki Iwata,
  • Tetsuji Yokoyama,
  • Akio Niimi,
  • Michiaki Mishima

DOI
https://doi.org/10.1016/j.alit.2017.02.003
Journal volume & issue
Vol. 66, no. 3
pp. 404 – 410

Abstract

Read online

Type-2/eosinophilic inflammation plays a pivotal role in asthma. The identification of severe type-2/eosinophilic asthma is important for improving the management of patients with asthma. Therefore, efforts to develop non-invasive biomarkers for type-2/eosinophilic airway inflammation have been made during this decade. Currently, fraction of exhaled nitric oxide (FeNO) and serum periostin levels are considered markers of type-2/eosinophilic inflammation in asthma. However, a single-marker approach has limited the ability to diagnose severe type-2/eosinophilic asthma accurately and predict disease outcomes precisely. The present article reviews the utility of FeNO and serum periostin levels in a single-marker approach and in a multiple-marker approach in identifying patients with severe type-2/eosinophilic asthma. Furthermore, based on a sub-analysis of the Kinki Hokuriku Airway disease Conference (KiHAC), geno-endo-phenotypes of patients were stratified into four groups according to the FeNO and serum periostin levels.

Keywords